CVS Health Corp (CVS)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $114.32B
Last updated: Nov 17, 2026 at 11:04 AM ET
CVS Health Corp (CVS) Earnings: Report Dates and Results
CVS Health (CVS) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, CVS Health reported EPS of $2.09, above the $1.62 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CVS has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 1.8% below the $1.09 reported for the quarter ended Dec 31, 2025.
CVS Earnings Call
The latest CVS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CVS beat 38 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $108.40B, up 5.4% from $102.87B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.09 | $1.62 | $1.52 - $1.87 | +29.01% | Beat | +30.6% | 23 | 5 up, 1 down | Nov 4, 2026 | $108.40B |
| Jun 30, 2026 | $2.58 | $1.87 | $1.58 - $1.94 | +37.97% | Beat | +42.5% | 23 | 3 up, 0 down | Aug 5, 2026 | $106.10B |
| Mar 31, 2026 | $2.57 | $2.21 | $2.10 - $2.38 | +16.29% | Beat | +14.2% | 22 | 3 up, 11 down | May 6, 2026 | $100.43B |
| Dec 31, 2025 | $1.09 | $1.00 | $0.93 - $1.08 | +9.00% | Beat | -8.4% | 24 | 2 up, 0 down | Feb 10, 2026 | $105.69B |
| Sep 30, 2025 | $1.60 | $1.36 | $1.23 - $1.53 | +17.65% | Beat | +46.8% | 24 | 3 up, 4 down | Oct 29, 2025 | $102.87B |
| Jun 30, 2025 | $1.81 | $1.46 | $1.35 - $1.72 | +23.97% | Beat | -1.1% | 23 | 3 up, 2 down | Jul 31, 2025 | $98.92B |
| Mar 31, 2025 | $2.25 | $1.67 | $1.41 - $1.91 | +34.73% | Beat | +71.8% | 22 | 3 up, 1 down | May 1, 2025 | $94.59B |
| Dec 31, 2024 | $1.19 | $0.92 | $0.45 - $1.09 | +29.35% | Beat | -43.9% | 23 | 0 up, 5 down | Feb 12, 2025 | $97.71B |
| Sep 30, 2024 | $1.09 | $1.46 | $1.05 - $1.99 | -25.34% | Miss | -50.7% | 22 | 0 up, 1 down | Nov 6, 2024 | $95.43B |
| Jun 30, 2024 | $1.83 | $1.73 | $1.60 - $2.02 | +5.78% | Beat | -17.2% | 22 | 0 up, 1 down | Aug 7, 2024 | $91.23B |
| Mar 31, 2024 | $1.31 | $1.70 | $1.62 - $1.99 | -22.94% | Miss | -40.5% | 22 | 0 up, 3 down | May 1, 2024 | $88.44B |
| Dec 31, 2023 | $2.12 | $1.99 | N/A | +6.53% | Beat | +6.5% | 19 | 6 up, 1 down | Feb 7, 2024 | $93.81B |
| Sep 30, 2023 | $2.21 | $2.13 | $2.01 - $2.21 | +3.76% | Beat | +2.8% | 20 | 2 up, 0 down | Nov 1, 2023 | $89.76B |
| Jun 30, 2023 | $2.21 | $2.12 | $1.91 - $2.40 | +4.25% | Beat | -7.9% | 22 | 3 up, 1 down | Aug 2, 2023 | $88.92B |
| Mar 31, 2023 | $2.20 | $2.09 | $1.92 - $2.19 | +5.26% | Beat | -0.9% | 21 | 3 up, 1 down | May 3, 2023 | $85.28B |
| Dec 31, 2022 | $1.99 | $1.93 | $1.89 - $1.96 | +3.11% | Beat | +0.5% | 19 | 6 up, 0 down | Feb 8, 2023 | $83.85B |
| Sep 30, 2022 | $2.15 | $1.99 | $1.92 - $2.08 | +8.04% | Beat | +9.1% | 21 | 3 up, 0 down | Nov 2, 2022 | $81.16B |
| Jun 30, 2022 | $2.40 | $2.18 | $2.10 - $2.37 | +10.09% | Beat | -0.8% | 23 | 3 up, 0 down | Aug 3, 2022 | $80.64B |
| Mar 31, 2022 | $2.22 | $2.15 | $1.97 - $2.41 | +3.26% | Beat | +8.8% | 20 | 2 up, 1 down | May 4, 2022 | $76.83B |
| Dec 31, 2021 | $1.98 | $1.88 | N/A | +5.32% | Beat | +52.3% | 15 | N/A | Feb 9, 2022 | $76.60B |
| Sep 30, 2021 | $1.97 | $1.79 | $1.69 - $1.93 | +10.06% | Beat | +18.7% | 22 | N/A | Nov 3, 2021 | $73.79B |
| Jun 30, 2021 | $2.42 | $2.07 | $1.85 - $2.24 | +16.91% | Beat | -8.3% | 22 | N/A | Aug 4, 2021 | $72.62B |
| Mar 31, 2021 | $2.04 | $1.72 | $1.49 - $1.80 | +18.60% | Beat | +6.8% | 22 | N/A | May 4, 2021 | $69.10B |
| Dec 31, 2020 | $1.30 | $1.24 | $1.17 - $1.40 | +4.84% | Beat | -24.9% | 23 | N/A | Feb 16, 2021 | $69.55B |
| Sep 30, 2020 | $1.66 | $1.34 | $1.24 - $1.39 | +23.88% | Beat | -9.8% | 25 | N/A | Nov 6, 2020 | $67.06B |
| Jun 30, 2020 | $2.64 | $1.92 | $1.66 - $2.17 | +37.50% | Beat | +39.7% | 23 | N/A | Aug 5, 2020 | $65.34B |
| Mar 31, 2020 | $1.91 | $1.63 | $1.54 - $1.78 | +17.18% | Beat | +17.9% | 22 | N/A | May 6, 2020 | $66.75B |
| Dec 31, 2019 | $1.73 | $1.69 | $1.65 - $1.75 | +2.37% | Beat | -19.2% | 24 | N/A | Feb 12, 2020 | $66.89B |
| Sep 30, 2019 | $1.84 | $1.77 | $1.75 - $1.79 | +3.95% | Beat | +6.4% | 24 | N/A | Nov 6, 2019 | $64.81B |
| Jun 30, 2019 | $1.89 | $1.69 | $1.68 - $1.71 | +11.83% | Beat | +11.8% | 24 | N/A | Aug 7, 2019 | $63.43B |
| Mar 31, 2019 | $1.62 | $1.51 | $1.43 - $1.63 | +7.28% | Beat | +9.5% | 23 | N/A | May 1, 2019 | $61.65B |
| Dec 31, 2018 | $2.14 | $2.05 | $1.84 - $2.22 | +4.39% | Beat | +11.5% | 12 | N/A | Feb 20, 2019 | $54.42B |
| Sep 30, 2018 | $1.73 | $1.71 | $1.69 - $1.78 | +1.17% | Beat | +15.3% | 21 | N/A | Nov 6, 2018 | $47.49B |
| Jun 30, 2018 | $1.69 | $1.61 | $1.59 - $1.65 | +4.97% | Beat | +27.1% | 19 | N/A | Aug 8, 2018 | $46.92B |
| Mar 31, 2018 | $1.48 | $1.41 | $1.27 - $1.48 | +4.96% | Beat | +26.5% | 21 | N/A | May 2, 2018 | $45.74B |
| Dec 31, 2017 | $1.92 | $1.88 | $1.87 - $1.92 | +2.13% | Beat | +12.3% | 22 | N/A | Feb 8, 2018 | $48.41B |
| Sep 30, 2017 | $1.50 | $1.49 | $1.47 - $1.51 | +0.67% | Beat | -8.5% | 21 | N/A | Nov 6, 2017 | $46.18B |
| Jun 30, 2017 | $1.33 | $1.31 | $1.29 - $1.33 | +1.53% | Beat | +0.8% | 23 | N/A | Aug 8, 2017 | $45.69B |
| Mar 31, 2017 | $1.17 | $1.10 | N/A | +6.36% | Beat | -0.8% | N/A | N/A | May 2, 2017 | $44.51B |
| Dec 31, 2016 | $1.71 | $1.67 | N/A | +2.40% | Beat | +11.8% | N/A | N/A | Feb 9, 2017 | $45.99B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.75, up 24.5% from the year before. It was $5.85 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.75 | +24.5% |
| Dec 31, 2024 | $5.42 | -38.0% |
| Dec 31, 2023 | $8.74 | N/A |
| Dec 31, 2022 | $8.76 | +4.2% |
| Dec 31, 2021 | $8.41 | +12.0% |
| Dec 31, 2020 | $7.51 | +6.1% |
| Dec 31, 2019 | $7.08 | N/A |
| Dec 31, 2018 | $7.04 | +18.9% |
| Dec 31, 2017 | $5.92 | +1.2% |
| Dec 31, 2016 | $5.85 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,163 | 17 | |
| 2026Q2 | Jun 30, 2026 | 7,745 | 13 | |
| 2026Q1 | Mar 31, 2026 | 8,674 | 14 | |
| 2025Q4 | Dec 31, 2025 | 8,247 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,360 | 14 | |
| 2025Q2 | Jun 30, 2025 | 7,895 | 15 | |
| 2025Q1 | Mar 31, 2025 | 8,733 | 14 | |
| 2024Q4 | Dec 31, 2024 | 9,129 | 13 |
2026Q3 Earnings Call
Opening remarks
Larry McGrath Executive Vice President of Capital Markets Good morning, and welcome to the CVS Health Third Quarter 2026 Earnings and Business Update Call and Webcast. I am Larry McGrath, executive vice president of capital markets at CVS Health. I am joined this morning by David Joyner, Chairman and Chief Executive Officer, and Brian O. Newman, Chief Financial Officer. Following our prepared remarks, we will host a question-and-answer session that will include additional members of the leadership team. Our press releases and slide presentations have been posted to our website, along with our Form 10-Q filed this morning with the SEC. Today's call is also being broadcast on our website. During this call, we will make certain forward-looking statements. Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results. We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties, in particular those described in the cautionary statement concerning forward-looking statements and risk factors in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q filed this morning, and our recent filings on Form 8-K, including this morning's earnings press release. During this call, we will use certain non-GAAP measures when talking about the company's financial performance and financial condition. You can find a reconciliation of these non-GAAP measures in this morning's press release and in the reconciliation document posted to the Investor Relations portion of our website. With that, I would like to turn the call over to David. David?
J. David Joyner Chairman and Chief Executive Officer Thank you, Larry, and good morning, everyone. Our organization has a long and distinguished history, and in my 40 years at this company, there has been one constant: We act, we evolve, and we proactively shape the future of health care. Today, we announced our intention to separate into two independent publicly traded companies. This decision marks the next important chapter in the evolution of CVS Health. We are creating two distinct leaders in health care. The first will be a health care solutions company that brings together medical, pharmacy, specialty, and care delivery capabilities, integrated where it matters. In the interim period, we are referring to this business as CVS Health. The second company will be a leading national retail pharmacy and community health care company. This business will be named CVS Pharmacy. Both companies will be led by experienced leadership teams, have a clear right to win in their respective markets, and, we expect, will be supported by solid investment-grade balance sheets, enabling each company to pursue disciplined and tailored capital allocation.
Frequently Asked Questions About CVS
When is CVS Health's next earnings date?
CVS Health's next earnings report is expected for Feb 8, 2027.
Did CVS beat earnings estimates last quarter?
Yes. CVS Health reported EPS of $2.09 for the quarter ended Sep 30, 2026, above the $1.62 estimate, a 29.01% surprise.
What EPS do analysts expect from CVS next quarter?
The consensus EPS estimate for CVS Health for the quarter ending Dec 31, 2026 is $1.07 from 26 analysts, with estimates from $0.95 to $1.34.
How often does CVS beat earnings estimates?
CVS Health beat the EPS estimate in each of the last 8 quarters, with an average surprise of +24.75%.
CVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts